Vaccine acquisitions could pave the way for Bavarian Nordic's 2025 ambitions
![Photo: Bavarian Nordic / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13797823.ece/ALTERNATES/schema-16_9/doc7jz7c9zl3eq124wuvdrm.jpg)
A lot is going on at Bavarian Nordic: the transfer of Glaxosmithkline’s vaccines Rabipur and Encepur, three ongoing clinical cancer studies, the development of RSV and Covid-19 vaccines, an expansion of production facilities in Denmark and a liquid-frozen formulation of the company’s smallpox vaccine.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Bavarian Nordic expects revenue setback in 2022
For subscribers